Biotech

All Articles

AstraZeneca blog posts records on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early look at the functionality of its own in-house antibody-...

iTeos- GSK's TIGIT superstar presents significant enhancement

.After introducing a stage 3 launch based on positive midstage end results, iTeos and GSK are eventu...

More collaborative FDA can accelerate rare condition R&ampD: file

.The FDA needs to be actually extra available and joint to let loose a surge in commendations of rar...

Zenas, MBX, Bicara scalp to Nasdaq in scorching day for biotech IPOs

.It is actually an uncommonly active Friday for biotech IPOs, along with Zenas BioPharma, MBX as wel...

Atea's COVID antiviral fails to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has actually neglected an additional COVID-19 trial, yet the biotec...

Neurocrine's quote to save mental illness prospect falls short

.Neurocrine Biosciences' mental illness plan pivot has neglected. The biotech was actually not able ...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in a late entry to the radioligand gathering, paying out one hundred mi...

F 2G rears $100M for 2nd attempt to obtain brand new antifungal to market

.After F2G's very first attempt to receive a brand-new course of antifungal to market was thwarted b...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 courses amid profitability tensions

.Moderna has promised to reduce R&ampD costs by $1.1 billion through 2027. The selection to shrink t...

Sanofi's $80M bank on Fulcrum dystrophy medicine ends in stage 3 go bust

.Just 4 months after Sanofi wager $80 thousand in ahead of time cash on Pivot Therapeutics' losmapim...